AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-05-04. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
The converge of affordable technology from POS industry, cloud infrastructure, mobile platforms and low cost bandwidth is largely fuelling the adoption of technology by small retailers. Entrepreneurs are building highly affordable technology products which are likely to bridge the digital divide between online and offline retail. Amartya Sen, the Indian-born Nobel Prize–winning economist, in a December 2011 interview claims foreign direct investment in multi brand retail can be good thing or bad thing, depending on the nature of the investment. Quite often, claims Professor Sen, FDI is a good thing for India.
=== Vegetation and flora === In Belize forest cover is around 56% of the total land area, equivalent to 1,277,050 hectares (ha) of forest in 2020, down from 1,600,030 hectares (ha) in 1990. In 2020, naturally regenerating forest covered 1,274,670 hectares (ha) and planted forest covered 2,390 hectares (ha). Of the naturally regenerating forest 0% was reported to be primary forest (consisting of native tree species with no clearly visible indications of human activity) and around 59% of the forest area was found within protected areas. Around 20% of the country's land is covered by cultivated land (agriculture) and human settlements. Belize had a 2018 Forest Landscape Integrity Index mean score of 6.15/10, ranking it 85th globally out of 172 countries. Savanna, scrubland and wetland constitute the remainder of Belize's land cover. Important mangrove ecosystems are also represented across Belize's landscape. Four terrestrial ecoregions lie within the country's borders – the Petén–Veracruz moist forests, Belizian pine forests, Belizean Coast mangroves, and Belizean Reef mangroves. As a part of the globally significant Mesoamerican Biological Corridor that stretches from southern Mexico to Panama, Belize's biodiversity – both marine and terrestrial – is rich, with abundant flora and fauna. Belize is also a leader in protecting biodiversity and natural resources.
=== Imaging === The role of MRI or ultrasound imaging in the diagnosis of CTS is unclear. Their routine use is not recommended. Morphological MRI has high sensitivity but low specificity for CTS. High signal intensity may suggest accumulation of axonal transport, myelin sheath degeneration, or edema. However, more recent quantitative MRI techniques, which derive repeatable, reliable, and objective biomarkers from nerves and skeletal muscle, may have utility, including diffusion-weighted (typically diffusion tensor) MRI, which has demonstrable normal values and aberrations in carpal tunnel syndrome.
Sources: en.wikipedia.org
=== Extracellular vesicle cross-talk === Recent studies have highlighted the involvement of RAGE (Receptor for Advanced Glycation End-products) in mediating the intercellular communication through extracellular vesicles (EVs), particularly during inflammatory responses. RAGE, known for its interaction with various ligands including advanced glycation end-products (AGEs), plays a key role in the biogenesis and secretion of EVs from stressed or damaged cells. Extracellular vesicles, such as exosomes, are small lipid-bound vesicles that facilitate cell-to-cell communication by transferring molecular cargo including proteins, lipids, and RNAs between cells. Recent evidence suggests that RAGE-associated vesicular pathways contribute to the exacerbation of inflammation by enabling pro-inflammatory signaling between cells. Specifically, a study from 2023 demonstrated that β-cells exposed to cytokine-induced stress release EVs enriched with RAGE ligands, which were found to further activate RAGE signaling pathways in neighboring cells, promoting inflammatory responses and impairing insulin secretion. These EV-mediated effects were shown to propagate inflammation across multiple cell types, indicating that RAGE-associated vesicles may play a pivotal role in amplifying the immune response in metabolic disorders like diabetes. Another study from 2024 reported that EVs containing RAGE ligands could be detected in the bloodstream of patients with early-stage diabetes, suggesting the potential utility of these vesicles as biomarkers for early diagnosis of inflammatory diseases.
Singapore's diversity of cuisine is touted as a reason to visit the country, due to its combination of convenience, variety, quality, and price. Local food items generally relate to a particular ethnicity – Chinese, Malay and Indian; but the diversity of cuisine has increased further by the hybridisation of different styles (e.g., the Peranakan cuisine, a mix of Chinese and Malay cuisine). In hawker centres, cultural diffusion is exemplified by traditionally Malay hawker stalls also selling Tamil food. Hainanese chicken rice, based on the Hainanese dish Wenchang chicken, is considered Singapore's national dish. The city-state has a burgeoning food scene ranging from hawker centres (open-air), food courts (air-conditioned), coffee shops (open-air with up to a dozen hawker stalls), cafes, fast food, simple kitchens, casual, celebrity and high-end restaurants. Cloud kitchens and food delivery are also on the rise, with 70% of residents ordering from delivery apps at least once a month. Many international celebrity chef restaurants are located within the integrated resorts. Religious dietary strictures exist (Muslims do not eat pork and Hindus do not eat beef), and there is also a significant group of vegetarians. The Singapore Food Festival which celebrates Singapore's cuisine is held annually in July. Prior to the 1980s, street food was sold mainly by immigrants from China, India, and Malaysia to other immigrants seeking a familiar taste. In Singapore, street food has long been associated with hawker centres with communal seating areas.
Driver, who is incarcerated at Salinas Valley State Prison (CDCR #D-35391), has filed numerous pro se civil rights actions under 42 U.S.C. § 1983 at multiple California facilities. While his lawsuits have consistently been dismissed on procedural grounds, he has appealed some decisions to the U.S. Court of Appeals for the Ninth Circuit. In May and June 2022, Adilah Patton, a 28‑year‑old pretrial detainee in Indianapolis, was forcibly injected twice with Invega Sustenna while in custody at the Marion County Adult Detention Center. A federal lawsuit filed on her behalf alleges that the injections were administered without a medical assessment, a prescription, or the consent of her court‑appointed guardian. The lawsuit describes the injections as assault, battery, excessive force, and violations of the Fourteenth Amendment right to informed consent. In September 2024, Haitian immigrant Cassandra Fameux filed a criminal complaint alleging that her husband, Michigan anesthesiologist Dr. Paul Gregory St. Claire, and psychiatrist Dr. Dominic Barberio forcibly injected her monthly from 2017 to 2021 with unprescribed Invega Sustenna—sometimes at doses up to 256 mg—as "punishment" when her husband was angry. Divorce court testimony and a recorded conversation indicate Barberio admitted she was not schizophrenic; two psychiatrists found she had PTSD, not bipolar disorder or schizophrenia. A subsequent police investigation led to a recommendation that her husband be charged with domestic assault.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.